Market capitalization | $2.44b |
Enterprise Value | $2.64b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.99 |
P/S ratio (TTM) P/S ratio | 4.62 |
P/B ratio (TTM) P/B ratio | 12.25 |
Revenue growth (TTM) Revenue growth | 32.29% |
Revenue (TTM) Revenue | $528.30m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
12 Analysts have issued a Amicus Therapeutics, Inc. forecast:
12 Analysts have issued a Amicus Therapeutics, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 528 528 |
32%
32%
|
|
Gross Profit | 467 467 |
32%
32%
|
|
EBITDA | 43 43 |
165%
165%
|
EBIT (Operating Income) EBIT | 34 34 |
146%
146%
|
Net Profit | -56 -56 |
63%
63%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
Head office | United States |
CEO | Bradley Campbell |
Employees | 499 |
Founded | 2002 |
Website | www.amicusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.